DBV.PA - DBV Technologies S.A.

Paris - Paris Delayed Price. Currency in EUR

DBV Technologies S.A.

177-181 avenue Pierre Brossolette
Montrouge 92120
France
33 1 55 42 78 78
http://www.dbv-technologies.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees322

Key Executives

NameTitlePayExercisedYear Born
Mr. Daniel TasséCEO & Director47.7kN/A1960
Dr. Pierre-Henri BenhamouCo-Founder & Member of Scientific Advisory Board1.45MN/A1955
Dr. Laurent MartinDeputy Chief Exec. Officer231.51kN/A1967
Mr. Sébastien RobitailleChief of Staff & Interim Chief Financial OfficerN/AN/A1970
Dr. Hugh A. SampsonChief Scientific Officer & Member of Scientific Advisory BoardN/AN/A1949
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Corporate Governance

DBV Technologies S.A.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.